Autism: Non-Drug Biological Treatments

  • Mary Coleman


In the field of biological treatments of autistic children, therapies tend to fall into two general categories. First are the non-specific therapies which are given to any child who has autistic symptoms regardless of etiology. Dr. Campbell, who has made the major contributions to the field of pharmacotherapy in autism, has reviewed the drugs now available for this patients group. Under this category of non-specific therapies, we will look at the treatments other than drugs which have been proposed for autistic children.


Lactic Acidosis Autistic Child Ketogenic Diet Sodium Valproate Autistic Symptom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Antonarakis, S. E. (1989). Diagnosis of genetic disorders at the DNA level. New England Journal of Medicine, 320, 153–163.PubMedCrossRefGoogle Scholar
  2. Becker, M. A., Raivio, K. O., Balmy, B., Adams, W. B., and Nyhan, W. L. (1980). Variant human phosphoribosylpyrophosphate synthetase altered in regulatory and catalytic functions. Journal of Clinical Investigation, 65, 109–120.PubMedCrossRefGoogle Scholar
  3. Berry, H. K., O’Grady, D. J., Perlmutter, L. J., and Bofmger, M. K. (1979). Intellectual development and academic achievement of children treated early for phenylketonuria. Developmental Medicine and Child Neurology, 21,311-320.Google Scholar
  4. Blomquist, H., Bohman, M., Edvinsson, S., Gillberg, C., Gustayson, K. H., Holmgren, G., and Wahlstróm, J. (1985) Frequency of the fragile X syndrome in infantile autism. Clinical Genetics, 27, 113–117.PubMedCrossRefGoogle Scholar
  5. Brown, W. T., Cohen, I., Fisch, G., Wolf-Schein, E. G., Jenkins, V. A., Malik, M. N., and Jenkins, E. C. (1986). High dose folic acid treatment of fragile X males. American Journal of Medical Genetics, 23, 263–271.PubMedCrossRefGoogle Scholar
  6. Campbell, M., Small, A. M., Collins, P. J., Friedman, E., David, R., and Genieser, N. (1976). Levodopa and levoamphetamine: a crossover study in young schizophrenic children. Current Therapies Research, 19, 70–86.Google Scholar
  7. Campbell, M., Fish, B., David, R., Shapiro, T., Collins, P., and Koh, C. (1972). Response to triiodathyronine and dextroamphetamine–a study of preschool schizophrenic children. Journal of Autism and Childhood Schizophrenia, 2, 343–358.PubMedCrossRefGoogle Scholar
  8. Cohen, D. J., Shaywitz, B. A., Johnson, W. T., and Bowers, Jr, M. B. (1974). Biogenic amines in autistic and atypical children. Cerebrospinal fluid measures of homovanillic acid and 5-hydroxyindoleacetic acid. Archives of General Psychiatry, 31, 845–853.PubMedCrossRefGoogle Scholar
  9. Coleman, M. (1989). A medical approach to self-abuse of the eyes (in press).Google Scholar
  10. Coleman, M., and Blass, J. P. (1985). Autism and lactic acidosis. Journal of Autism and Developmental Disorders, 15,1-8.Google Scholar
  11. Coleman, M., and Gillberg, C. (1985). The biology of the Autistic Syndromes. New York: Praeger Scientific. Pages cited: a - 77; b - 185; c - 80; d - 182; e - 151; f - 45.Google Scholar
  12. Coleman, M., Landgrebe, M., and Landgrebe, A. (1976a) Purine autism. In The Autistic Syndromes. M. Coleman (Ed.), Amsterdam: North-Holland.Google Scholar
  13. Coleman, M., Landgrebe, M., and Landgrebe, A. (1976b). Calcium studies and their relationship to celiac disease in autistic patients. In The Autistic Syndromes. M. Coleman (Ed.), Amsterdam: North Holland.Google Scholar
  14. Coleman, M., Sobel, S., Bhagavan, H. N., Coursin, D. B., Marquardt, A., Guay, M., and Hunt, C. (1985). A double blind study of vitamin B6 in Down’s syndrome infants. Part I–Clinical and biochemical results. Journal of Mental Deficiency Research, 29, 233–240.PubMedGoogle Scholar
  15. Coleman, M., Landgrebe, M., and Landgrebe, A. (1986). Purine seizure disorders. Epilepsia, 23, 263–269.CrossRefGoogle Scholar
  16. Deutsch, S. I. Campbell, M., Sachar, E., Green, W., and David, R. (1985). Plasma growth hormone response to oral L-DOPA in infantile autism. Journal of Autism and Developmental Disorders, 15, 205-212.Google Scholar
  17. Friedman, E. (1969). The autistic syndrome and phenylketonuria. Schizophrenia, 1, 249–261.Google Scholar
  18. Froster-Iskenius, U., Bodeker, K., Oepen, T., Matthes, R., Piper, U., and Schwinger, E. (1986). Folic acid treatment in males and females with fragile X syndrome. American Journal of Medical Genetics, 23, 273–289.PubMedCrossRefGoogle Scholar
  19. Gamier, C., Conroy, E., Barthélémy, C., Leddet, B., Garreau, B., Muh, J. P., and Lelord, G. (1986). Dopamine-beta-hydroxylase (DBH) and homovanillic acid (HVA) in autistic children. Journal of Autism and Developmental Disorders, 16, 23–30.CrossRefGoogle Scholar
  20. Garreau, B., Barthélémy, C., Jouve, J., Bruneau, N., Muh, J. P., and Lelord, G. (1988). Urinary homovanillic acid levels of autistic children. Developmental Medicine and Child Neurology, 30,93-98.Google Scholar
  21. Geller, E., Yuwiler, A., Freeman, B. J., and Ritvo, E. (1988). Platelet size, number, and serotonin content in the blood of autistic, childhood schizophrenic and normal children. Journal ofAutism and Developmental Disorders, 18,119-126.Google Scholar
  22. Gillberg, C., and Schaumann, H. (1983). Epilepsy presenting as infantile autism? Two case studies. Neuropediatrics, 14,206-212.Google Scholar
  23. Gillberg, C., and Svennerholm, L. (1987). CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood. British Journal of Psychiatry, 151, 89–94.PubMedCrossRefGoogle Scholar
  24. Gruber, H. E., Jansen, I., Willis, R. C., and Seegmiller, J. E. (1985). Alteration of the inosinate branchpoint enzymes in cultured human lymphoblasts. Acta Biochemical Biopsy, 846,135-144.Google Scholar
  25. Grutr, W. (1963). “Angeborene Stoffwechselstorungen and Schwachsinn am Beispiel der Phenylketonurie”. Stuttgart: F. Enke Verlag.Google Scholar
  26. Hagerman, R., McBogg, P., and Hagerman, P. (1983). ’The fragile X syndrome: History, diagnosis and treatment“, Colorado: Spectrum, Dillon.Google Scholar
  27. Hagerman, R J., Jackson, A. W., Levitas, A., Braden, M., McBogg, P., Kemper, M., McGavran, L., Barry, R, Matus, I., and Hagerman, P. J. (1986). Oral folic acid versus placebo in the treatment of males with the fragile X syndrome. American Journal of Medical Genetics, 23, 241–262.Google Scholar
  28. Ho, H. H., Lockitch, G., Eaves, L., and Jacobson, B. (1986). Blood serotonin concentrations and fenfluramine therapy in autistic children. Journal of Pediatrics, 108,465-469.Google Scholar
  29. Jaeken, J., and van den Berghe, G. (1984). An infantile autism syndrome characterised by the presence of succinylpurines in body fluids. Lance4 2, 1058–1061.Google Scholar
  30. Jonas, C., Etienne, T., Barthélémy, C., Jouve, J., and Mariotte, N. (1984). Interet clinique et biochimique de l’association vitamine B6 and magnesium dans le traitement de l’autisme residuel a rage adulte. Therapie, 39, 661–669.PubMedGoogle Scholar
  31. Kuperman, S., Beeghly, J., Burns, T., and Tsai, L. (1987). Association of serotonin concentration to behavior and IQ in autistic children. Journal of Autism and Developmental Disorders, 17,133-140.Google Scholar
  32. Launay, J-M., Bursztejn, C., Ferrari, P., Dreux, C., Braconnier, A., Zarifian, E., Lancrenon, S., and Fermanian, J. (1987). Catecholamine metabolism in infantile autism: a controlled study of 22 autistic children. Journal of Autism and Developmental Disorders, 17,333-347.Google Scholar
  33. Launay, J. M., Ferrari, P., Haimart, M., Bursztejn, C., Tabuteau, F., Braconnier, A., Pasques-Bondoux, D., Luong, C., and Dreux, C. (1988). Serotonin metabolism and other biochemical parameters in infantile autism. Neuropsychobiology, 112, 1 19.Google Scholar
  34. Lelord, G., Callaway, E., Muh, J. P., Arlot, J. C., Sauvage, D., Carreau, B., and Domenech, J. (1978). L’acide homovanilique urinaire et ses modifications par ingestion de vitamine B6: exploration fonctionnelle dans l’autisme de l’enfant? Revue Neurologique, 134,797-801.Google Scholar
  35. Lelord, G., Calloway, E., Muh, J. P., and Martineau, J. (1982). Clinical and biological effects of high doses of vitamin B6 and magnesium on autistic children. Acta Vitaminologica et Enzymologica, 4, 27–44.PubMedGoogle Scholar
  36. Lewis, E. (1959). The developemnt of concepts in a girl after dietary treatment for phenyketonuria. British Journal of Medical Psychology, 32, 282–287.PubMedCrossRefGoogle Scholar
  37. Lowe, T. L., Tanaka, K., Seashore, M. R, Young, J. G., and Cohen, D. J. (1980). Detection of phenylketonuria in autistic and psychotic children. Journal of the American Medical Association, 243,126-128.Google Scholar
  38. Minderaa, R. B., Anderson, G., Volkmar, F., Akkerhuis, G. W., and Cohen, D. J. (1987). Urinary 5-hydroxyindoleacetic acid and whole blood serotonin and tryptophan in autistic and normal subjects. Biological Psychiatry, 22, 933–940.PubMedCrossRefGoogle Scholar
  39. Martineau, J., Barthélémy, C., Carreau, B., and Lelord, G. (1985). Vitamin B 6, magnesium and combined B 6-Mg: therapeutic effects in childhood autism. Biological Psychiatry, 20,467-478.Google Scholar
  40. Martineau, J., Barthélémy, C., and Lelord, G. (1966). Long-term effects of combined vitamin B 6-magnesium administration in an autistic child. Biological Psychiatry, 21, 511-518.Google Scholar
  41. Martineau, J., Barthélémy, C., Cheliakine, C., and Lelord, G. (1988). Brief report: an open middle-term study of combined vitamin B6-magnesium in a subgroup of autistic children selected on their sensitivity to this treatment. Journal of Autism and Developmental Disorders, 18, 435–447.PubMedCrossRefGoogle Scholar
  42. McElroy, S. L., Keck, P., and Pope, H. G. (1987). Sodium valproate: its use in primary psychiatric disorders. Journal of Clinical Pharmacology, 7, 16–24.Google Scholar
  43. Olsson, I., Steffenburg, S., and Gillberg, C. (1988). Epilepsy in autism and autistlike conditions: a population-based study. Archives of Neurology, 45,666-668.Google Scholar
  44. Reiss, A. (1988). Cerebellar hypoplasia and autism. New England Journal of Medicine, 319,1152-1153.Google Scholar
  45. Rimland, B., Callaway, E., and Dreyfus, P. (1978). The effects of high doses of vitamin B6 on autistic children. A double-blind crossover study. American Journal of Psychiatry, 135, 472–475.PubMedGoogle Scholar
  46. Ritvo, E. R, Yuwiler, A., Geller, E., Kales, A., Rashkis, S., Schicor, A., Plotkin, S., Axelrod, R, and Howard, C. (1971). Effects of L-DOPA in autism. Journal of Autism and Childhood Schizophrenia, 1, 190–205.PubMedCrossRefGoogle Scholar
  47. Rosenberger-Debiesse, J., and Coleman, M. (1986). Brief report-preliminary evidence for multiple etiologies in autism. Journal of Autism and Developmental Disorders, 16, 385–392.PubMedCrossRefGoogle Scholar
  48. Scharr, R., and Freedman, D. (1961). Studies of 5-hydroxyindole metabolism in autistic and other mentally retarded children. Journal of Pediatrics, 58, 315–320.CrossRefGoogle Scholar
  49. Schaumburg, H., Kaplan, J., Windebank, A., Vick, N., Rasmus, S., Pleasure, D., and Brown, M. J. (1983). Sensory neuropathy from pyridoxine abuse. New England Journal of Medicine, 309, 445–448.CrossRefGoogle Scholar
  50. Sepe, J., Levy, H. L., and Mount, F. W. (1979). An evaluation of routine follow-up blood screening of infants for phenylketonuria. New England Journal of Medicine, 300, 606–609.PubMedCrossRefGoogle Scholar
  51. Turner, G., Robinson, H., Laing, S., and Purvis-Smith, S. (1986). Preventive screening for the fragile X syndrome. New England Journal of Medicine, 315,607-609.Google Scholar
  52. Watson, M. S., Leckman, J. F., Annex, B., Breg, W. R., Boles, D., Volkmar, F. R., and Cohen, D. J. (1984). Fragile X in a survey of 75 autistic males. New England Journal of Medicine, 310, 1462.Google Scholar
  53. Winsberg, B. B., Sverd, J., Castelles, S., Hurwic, M., and Perel, J. M. (1980). Estimation of monoamine and cyclic-AMP turnover and amino acid concentrations in the spinal fluid of autistic children, Neuropediatrie 11, 250–255.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Mary Coleman

There are no affiliations available

Personalised recommendations